Regulatory
Rapporteur

Write to the Editor at publications@topra.org

October 2023 | Vol. 20 | No.9

EDITORIAL

Veterinary medicines: the challenge of a new regulation

This edition of Regulatory Rapporteur focuses on topics and developments specific to veterinary medicines, from challenges arising from new veterinary regulations to measures ensuring the safe and effective use of medicines and vaccines.

READ HERE
By Birgit Roser and Kornelia Grein

FOCUS

Transition to the new QRD template for veterinary medicines

The product information template for veterinary medicines was updated from QRD V.8.2 to QRD v.9 to reflect requirements for labelling and packaging, and a five-year transition period has been set for existing market authorisations. This article discusses the key aspects that the revision entails for the years ahead.

READ HERE
By Elsa Vecino

FOCUS

Autogenous vaccines under Regulation (EU) 2019/6

Autogenous vaccines (AV) are now included in EU legislation for veterinary medicinal products following the implementation of Regulation (EU) 2019/6. The regulation acknowledges that AVs will require a specific set of manufacturing rules. This article reports on the work being completed to implement good manufacturing practice guidelines for AVs.

READ HERE
By Hans-Joachim Selbitz

FOCUS

Prequalification of veterinary vaccines and medicines

The WHO prequalification scheme assesses the quality and safety of human medicines. The European Commission is working to create a similar scheme for veterinary medicines and vaccines. This article summarises the main aspects of the scheme, its status of development and the expectations for the future.

READ HERE
By Kornelia Grein, Martin Ilott, David Mackay and Mark Sellers

FOCUS

EMA activities related to antiparasitic veterinary medicinal products

Renewed efforts have been made by the EMA, its Committee for Veterinary Medicinal Products and associated working parties to reflect evolving knowledge and requirements for veterinary medicinal products. This article provides an overview of current reflections and guidance for the development of antiparasitic veterinary medicinal products.

READ HERE
By Valentin Nicorescu and Barbara Cyrus

STANDALONE

Optimal materials selection in medical device development

During the development of a new medical device, regulatory requirements concerning biocompatibility should be considered at every stage. By adopting proactive approaches to biocompatible material section, manufacturers can have a high degree of certainty in building safe and effective products. This article discusses biological evaluation standards and ways to optimise material selection.

READ HERE
By Jocivania Oliveira da Silva and Marielle Fournier